Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Melanoma Screening

    Publikation: Bidrag til tidsskriftLetterpeer review

  2. Serum Anticytokine Autoantibody Levels Are Not Increased in Hidradenitis Suppurativa: A Case-Control Pilot Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Protein phosphatase, Mg2+/Mn2+-dependent 1D (PPM1D) mutations in haematological cancer

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Veronica Stolearenco
  • Trine B Levring
  • Helene Myrtue Nielsen
  • Lise Lindahl
  • Simon Fredholm
  • Martin Kongsbak-Wismann
  • Andreas Willerslev-Olsen
  • Terkild B Buus
  • Claudia Nastasi
  • Tengpeng Hu
  • Maria Gluud
  • Christophe Roger Michel Côme
  • Thorbjørn Krejsgaard
  • Lars Iversen
  • Charlotte Menné Bonefeld
  • Kirsten Grønbæk
  • Özcan Met
  • Anders Woetmann
  • Niels Ødum
  • Carsten Geisler
Vis graf over relationer

BACKGROUND: The thioredoxin-interacting protein (TXNIP) is involved in cellular metabolism and cell proliferation, and recently, deficient expression of TXNIP has been associated with progression and poor outcome for cancer patients.

OBJECTIVES: To assess TXNIP expression and function in malignant T cells from cutaneous T-cell lymphoma (CTCL).

METHODS: CTCL-derived malignant (MyLa2059, PB2B) and non-malignant (MyLa1850) cell lines were analysed by Western blotting and qPCR for TXNIP expression. Subsequently, the malignant CTCL cell lines were treated with GSK126 - an inhibitor of enhancer of zeste homolog 2 (EZH2) methyltransferase activity or assessed by bisulphite sequencing for TXNIP promoter methylation. Methylation was also assessed with the demethylating agent 5-azacytidine (5AZA). Finally, TXNIP was overexpressed in the malignant PB2B cell line via plasmid transduction, and the effect of TXNIP was further analysed by flow cytometry.

RESULTS: We report on low expression of TXNIP protein in all cell lines representing different subtypes and stages of CTCL when compared to non-malignant T cells. Epigenetic silencing and other mechanisms were involved in the repression of TXNIP whereas forced expression of TXNIP strongly inhibited proliferation of malignant T cells.

CONCLUSIONS: Epigenetic silencing and other as yet unknown mechanisms repress TXNIP expression in malignant T cells. As forced expression of TXNIP inhibits malignant proliferation, we propose that TXNIP is a putative tumour suppressor in CTCL.

OriginalsprogEngelsk
TidsskriftDermatology
Vol/bind237
Udgave nummer2
Sider (fra-til)283-290
ISSN1018-8665
DOI
StatusUdgivet - 2021

Bibliografisk note

© 2020 S. Karger AG, Basel.

ID: 61349929